Pharsight

Triesence patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6395294 HARROW EYE Method of visualization of the vitreous during vitrectomy
Jan, 2020

(4 years ago)

US8211880 HARROW EYE Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Mar, 2029

(4 years from now)

US8128960 HARROW EYE Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Dec, 2029

(5 years from now)

Triesence is owned by Harrow Eye.

Triesence contains Triamcinolone Acetonide.

Triesence has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Triesence are:

  • US6395294

Triesence was authorised for market use on 29 November, 2007.

Triesence is available in injectable;intravitreal dosage forms.

Triesence can be used as treatment of ophthalmic disorders, use for delineation (visualization) during a vitrectomy surgical procedure.

The generics of Triesence are possible to be released after 17 December, 2029.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 29 November, 2007

Treatment: Use for delineation (visualization) during a vitrectomy surgical procedure; Treatment of ophthalmic disorders

Dosage: INJECTABLE;INTRAVITREAL

More Information on Dosage

TRIESENCE family patents

Family Patents